Skip to content
thestock.space

On 6 Nov 2026, Pfizer was priced at ₹3,856.00, or 23.2× trailing earnings, against an industry P/E of 37.3×, and the shares are 28% below their 52-week high. It earns ROCE of 23% and ROE of 21%, and sales and net profit grew 1.3% and 5.0% a year over 3 years. It has almost no debt, and its dividend yield is 1.9%. It is a small-cap company with a market cap of ₹17,640 Cr, ranked 3rd of 15 Drug Manufacturers (General) companies by market cap; the shares fell 25% over the past year.

As of 6 Nov 2026Prices are delayed about 15 minutes; fundamentals are from the quarter ended Sep 2026.How we calculate this

past year
Open
₹3,869.60
Day high
₹3,881.90
Day low
₹3,797.20
Prev. close
₹3,856.90
Volume
40.1K

Health check

2 good · 2 fair · 2 to check
  • ReturnsBehind

    −24.6% over a year, better than 2 of 7 peers.

  • Price tagCheaper

    P/E 23.2 vs industry 37.3.

  • GrowthSlow

    Sales +1.3%, profit +5.0% a year over 3 years.

  • ProfitabilityAverage

    ROCE 22.9% vs peer median 23.6%.

  • Balance sheetFair

    Practically debt-free, Piotroski 5 of 9.

  • Red flagsNone found

    No warning signs in the headline numbers.

Compared with 7 industry peers. Computed from reported figures. Educational, not a recommendation.

Drug Manufacturers - General

14 listed peers. Screen the industry

Small cap

₹17,640 Cr, #3 of 15 in its industry by size.

Market sensitivity

Measuring against the NIFTY 50…

Key metrics

Last 12 months to Sep 2026: sales ₹2,654 Cr · profit ₹859 Cr
Market cap
₹17,640 Cr
Small cap
P/E
23.2
Industry 37.3
Price to book
4.02
Peers 18.55
Dividend yield
1.94%
ROE
20.9%
Peers 28.3%
ROCE
22.9%
Peers 23.6%
Debt to equity
0.04
Debt ₹197 Cr
EPS (TTM)
₹166.49
Face value ₹10
OPM (TTM)
36.7%
Net margin 32.4%
Sales growth
+13.2%
Latest quarter vs a year ago
Profit growth
+65.7%
Latest quarter vs a year ago
Price to sales
6.65
EV/EBITDA 15.6

Strengths and risks

Strengths

  • Return on equity of 20.9%.
  • Return on capital employed of 22.9%.
  • Practically debt-free.
  • Quarterly profit up 65.7% on a year ago.
  • Net margin of 32.4%.

No obvious red flags in the headline numbers.

Derived automatically from reported figures. Not a recommendation.

About Pfizer

Pfizer Limited engages in manufacturing, marketing, trading, and distribution of pharmaceutical products in India and internationally. It offers therapy area and products, such as vaccines, injectables and anti-infectives, inflammation and immunology, and internal medicine for cardiovascular care, oncology, respiratory, multivitamins and multimineral, neuroscience, women's health, gastroenterology, pain management, and nutrition, addressing. The company…

Headquarters
Mumbai
Employees
1,244
Sector
Healthcare
ISIN
INE182A01018
Website
pfizerltd.co.in

Price range

52 weeks

₹3,589.00₹5,339.00

Today

₹3,797.20₹3,881.90
Avg volume (3M)
54.1K
1-year return
minus 24.6%
From 52-week high
minus 27.8%

Peers · Drug Manufacturers - General

Compare with peersScreen the whole industry
Company
GLAXOGlaxosmithkline Pharmaceuticals2,524.80plus 0.98%42,77237.322.7355.4%63.9%34.1%5.7%19.3%2.26%minus 6.0%
RUBICONRubicon Research1,659.30minus 4.67%27,46895.619.3823.6%19.1%23.3%––0.09%plus 166.7%
PFIZERPfizer3,856.00minus 0.02%17,64023.24.0222.9%20.9%36.7%1.3%5.0%1.94%minus 24.6%
CORONACORONA Remedies2,441.10plus 2.58%14,93072.118.5529.0%28.3%21.3%16.6%29.7%0.41%plus 69.7%
MARKSANSMarksans Pharma303.70minus 3.20%13,76424.64.1317.5%15.2%22.5%16.7%16.2%0.30%plus 68.0%
SYMBIOTECSymbiotec Pharmalab1,513.60plus 19.04%9,726103.58.2614.3%11.2%10.7%16.8%67.3%0.00%plus 37.9%
SANOFICONRSanofi Consumer Healthcare India3,420.20minus 0.69%7,88828.222.64–80.4%37.8%––2.19%minus 29.5%
SANOFISanofi India3,283.10minus 2.75%7,56120.79.15–44.1%28.0%––3.75%minus 28.9%
Median of 7 peers–−0.69%13,76437.318.5523.6%28.3%23.3%16.7%24.5%0.41%37.9%

Quarterly results

Consolidated, ₹ crore
SalesSelect a row below to chart it
₹ CrSep 25Dec 25Mar 26Jun 26Sep 26
642645629653727
412417393406466
230228236248261
35.8%35.4%37.5%37.9%35.9%
41.938.240.744.847.3
2.122.11.53.4
14.314.314.814.314.4
–−58.29–132
255192269277423
26.0%26.1%25.7%26.1%25.9%
189142200204313
41.3231.0143.6844.6947.09

Profit & loss

Yearly, ₹ crore
Sales CAGR 3Y
+1.3%
Profit CAGR 3Y
+5.0%
EPS CAGR 3Y
+5.0%
ROE
20.9%
Net profitSelect a row below to chart it
₹ CrMar 2023Mar 2024Mar 2025Mar 2026
2,4222,1932,2812,519
–minus 9.5%+4.0%+10.4%
1,6081,5531,5391,614
814639742905
33.6%29.2%32.5%35.9%
91.4179171186
13.415.48.49.5
10662.360.857.7
37.25.5172−48.1
8247461,016976
24.3%26.1%24.5%26.0%
624551768722
–minus 11.6%+39.2%minus 5.9%
136.38120.51167.79157.92

Forecast

Your assumptions, not a prediction

Balance sheet

At each financial year end, ₹ crore
Total assetsSelect a row below to chart it
₹ CrMar 2023Mar 2024Mar 2025Mar 2026
45.845.845.845.8
3,1623,5504,1724,157
13494.510870.2
659539585649
4,0014,2294,9114,922
186152180157
8.30.68.220.9
1314.313.915.2
1,8402,0272,7833,088
1,9542,0361,9261,640
4,0014,2294,9114,922

Cash flow

Yearly, ₹ crore
Cash from operationsSelect a row below to chart it
₹ CrMar 2023Mar 2024Mar 2025Mar 2026
356257660968
−36.153.7−71.3−562
−346−235−205−798
−26.275.4383−392
−65−18.9−28.2−25.2
291238632942
−297−183−160−752

Shareholding pattern

Source: NSE filings
63.9%
promoters
  • Promoters63.92%
  • Public36.08%
  • As of 30 Sep 2026
QuarterSplitPromotersPublicPromoter change
30 Sep 202663.92%36.08%0.00
30 Jun 202663.92%36.08%0.00
31 Mar 202663.92%36.08%0.00
31 Dec 202563.92%36.08%0.00
30 Sep 202563.92%36.08%–

Major shareholders

NSE filing

Filings & events

News

No recent news coverage found.

My notes

Private to you